SynthesisScientific reports2022
A systematic review and meta-analysis on the prevalence of non-malignant, organic gastrointestinal disorders misdiagnosed as irritable bowel syndrome.
Synthesis in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- European guidelines for the diagnosis and treatment of pancreatic exocrine insufficiency: UEG, EPC, EDS, ESPEN, ESPGHAN, ESDO, and ESPCG evidence-based recommendations.United European gastroenterology journal · 2025Guideline
- Prevalence of irritable bowel syndrome in medical students: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Clinical and cost effectiveness of nurse led-structured management of diarrhoea predominant irritable bowel syndrome in primary care (Lincolnshire POACHER study); a randomised control trial.BMC primary care · 2026Trial
- Fructose malabsorption associated with functional abdominal bloating: Case-control study.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Pancreatic exocrine insufficiency.EClinicalMedicine · 2026Review
- Small intestinal microbiome, the underrated maestro of SIMO disease.FEMS microbiology reviews · 2026Review
- Association Between Irritable Bowel Syndrome and Hypothyroidism: Insights from Large-Scale Population-Based StudiesEndocrine, metabolic & immune disorders drug targets · 2026Article
- The road to Rome IV and beyond: Evolution, refinements and future considerations for the Rome criteria for functional gastrointestinal disorders.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Review
- Can Symptoms and Medical History Predict Outcomes for Hydrogen and Methane Breath Testing?The American journal of gastroenterology · 2025Article
- Common misconceptions and controversies in the management of irritable bowel syndrome.Nature reviews. Gastroenterology & hepatology · 2025Review
- Diagnostic strategy of irritable bowel syndrome: a low- and middle-income country perspective.Intestinal research · 2024Review
- Article
- Analysis of quality of life in patients after transgastric natural orifice transluminal endoscopic gallbladder-preserving surgery.World journal of gastrointestinal endoscopy · 2024Article
- Fecal Coprococcus, hidden behind abdominal symptoms in patients with small intestinal bacterial overgrowth.Journal of translational medicine · 2024Article
- Getting the BS out of Irritable Bowel Syndrome with Diarrhea (IBS-D): Let's Make a Diagnosis.Current gastroenterology reports · 2024Review
- Follow-Up of Microscopic Colitis Patients and Diarrhea Controls at 1 Year.Gastro hep advances · 2024Article
- Article
- Microbiota in Irritable Bowel Syndrome and Endometriosis: Birds of a Feather Flock Together-A Review.Microorganisms · 2023Review
- Irritable Bowel Syndrome and the Gut Microbiome: A Comprehensive Review.Journal of clinical medicine · 2023Review
- Can the Correlation of Periodontopathies with Gastrointestinal Diseases Be Used as Indicators in Severe Colorectal Diseases?Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatable gastrointestinal disorders in patients with symptoms typical for irritable bowel syndrome (IBS) may be overlooked. The prevalence of five gastrointestinal conditions-bile acid diarrhoea (BAD), carbohydrate malabsorption (CM), microscopic colitis (MC), pancreatic exocrine insufficiency (PEI) and small intestinal bacterial overgrowth (SIBO) was systematically assessed from studies including consecutive patients meeting diagnostic criteria for IBS. 4 databases were searched from 1978 to 2020. Studies were included if they evaluated the prevalence of these conditions in secondary healthcare setting. Estimated pooled rates were calculated and statistical heterogeneity between studies was evaluated using Q and I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.